Resverlogix (RVX) Competitors C$0.06 0.00 (0.00%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades RVX vs. PDP, EMH, PMN, DMT, MBX, HBP, GSD, IBT, BCT, and ACSTShould you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Pediapharm (PDP), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), Microbix Biosystems (MBX), Helix BioPharma (HBP), Devonian Health Group (GSD), IBEX Technologies (IBT), BriaCell Therapeutics (BCT), and Acasti Pharma (ACST). These companies are all part of the "biotechnology" industry. Resverlogix vs. Pediapharm Emerald Health Therapeutics ProMIS Neurosciences Small Pharma Microbix Biosystems Helix BioPharma Devonian Health Group IBEX Technologies BriaCell Therapeutics Acasti Pharma Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Which has preferable earnings & valuation, PDP or RVX? Resverlogix has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPediapharmC$11.16M5.95-C$16.15M-C$0.07-4.11ResverlogixN/AN/A-C$10.74M-C$0.05-1.10 Does the media favor PDP or RVX? In the previous week, Pediapharm's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score. Company Overall Sentiment Pediapharm Neutral Resverlogix Neutral Does the MarketBeat Community favor PDP or RVX? Resverlogix received 245 more outperform votes than Pediapharm when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 67.71% of users gave Pediapharm an outperform vote. CompanyUnderperformOutperformPediapharmOutperform Votes6567.71% Underperform Votes3132.29% ResverlogixOutperform Votes31084.01% Underperform Votes5915.99% Is PDP or RVX more profitable? Company Net Margins Return on Equity Return on Assets PediapharmN/A N/A N/A Resverlogix N/A N/A -34.90% SummaryResverlogix beats Pediapharm on 5 of the 7 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Resverlogix News Delivered to You Automatically Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVX vs. The Competition Export to ExcelMetricResverlogixBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$15.23MC$165.68MC$5.14BC$6.07BDividend Yield7.02%3.64%5.09%5.42%P/E Ratio-1.10115.5190.1326.16Price / SalesN/A18,531.021,117.091,332.85Price / Cash132.5012.8743.1082.30Price / Book-0.208.594.783.07Net Income-C$10.74M-C$20.67MC$120.31MC$295.24M7 Day PerformanceN/A-1.05%-1.92%-2.48%1 Month PerformanceN/A174.77%13.65%-0.91%1 Year PerformanceN/A134.18%28.34%33.65% Resverlogix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVXResverlogixN/AC$0.06flatN/A-21.4%C$15.23MN/A-1.1019PDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/AEMHEmerald Health TherapeuticsN/AC$0.26-3.8%N/A+0.0%C$52.28MC$13.02M-0.37161PMNProMIS NeurosciencesN/AN/AN/AN/AC$51.48MC$7,558.00-1.786Gap UpHigh Trading VolumeDMTSmall PharmaN/AC$0.15-6.3%N/A+0.0%C$50.37MC$-1,162.00-2.1413Gap DownHigh Trading VolumeMBXMicrobix BiosystemsN/AC$0.36+2.9%N/A+14.3%C$49.21MC$23.36M9.00N/ANews CoverageHigh Trading VolumeHBPHelix BioPharmaN/AC$0.95-5.0%N/AN/AC$46.57MN/A-4.759Gap DownGSDDevonian Health GroupN/AC$0.24+20.0%N/A+31.0%C$35.57MC$9.75M-12.006Gap UpIBTIBEX TechnologiesN/AC$1.44flatN/A+26.3%C$35.29MC$8M9.60N/ABCTBriaCell TherapeuticsN/AC$0.89-6.3%N/A-84.6%C$31.90MN/A-1.7816Gap UpHigh Trading VolumeACSTAcasti PharmaN/AC$0.58+1.8%N/A+0.0%C$25.87MC$115,000.00-1.0732 Related Companies and Tools Related Companies Pediapharm Competitors Emerald Health Therapeutics Competitors ProMIS Neurosciences Competitors Small Pharma Competitors Microbix Biosystems Competitors Helix BioPharma Competitors Devonian Health Group Competitors IBEX Technologies Competitors BriaCell Therapeutics Competitors Acasti Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:RVX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVX Stock Alerts